Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04897841 · ClinicalTrials.gov registry record · Phase 4
Obstetric Liposomal Bupivacaine Via Surgical Transversus Abdominis Plane Block for Post Cesarean Pain Control
A Phase 4 study, sponsored by University of Wisconsin, Madison.
- Completed
- Registry status
- Phase 4
- Development phase
- 60
- Enrollment target
NCT04897841 is a Phase 4 study that has completed, run by University of Wisconsin, Madison. The registered enrollment target is 60 participants.
The verdict
NCT04897841, a Phase 4 study, has completed, sponsored by University of Wisconsin, Madison.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 60 participants
- Enrollment target
Study Summary
This study seeks to identify whether the addition of liposomal bupivacaine to regular bupivacaine and saline administered via surgical transversus abdominis plane (TAP) block will reduce the cumulative opioid dose in the first 48 hours after cesarean. 60 women scheduled for cesarean at Unity-Point Health Meriter Hospital in Madison, Wisconsin will be enrolled and can be expect to be on study for up to 6 weeks post-partum.
Interventions
- DRUG Liposomal bupivacaine
- DRUG Bupivacaine Hydrochloride
- OTHER saline
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2021-10-11 |
| Est. Completion | 2022-10-13 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04897841
The ClinicalTrials.gov registry entry for NCT04897841 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Wisconsin, Madison, which has 1,039 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Liposomal bupivacaine is the first listed.
NCT04897841 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04897841 about?
NCT04897841 is a clinical study titled "Obstetric Liposomal Bupivacaine Via Surgical Transversus Abdominis Plane Block for Post Cesarean Pain Control". This study seeks to identify whether the addition of liposomal bupivacaine to regular bupivacaine and saline administered via surgical transversus abdominis plane (TAP) block will reduce the cumulative opioid dose in the first 48 hours after cesarean. 60 women scheduled for cesarean at Unity-Point H...
What is the current status of trial NCT04897841?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 60 participants. The study started on 2021-10-11. Estimated completion is 2022-10-13.
What interventions are being tested in trial NCT04897841?
The interventions under investigation include: Liposomal bupivacaine (DRUG), Bupivacaine Hydrochloride (DRUG), saline (OTHER).
Who is sponsoring clinical trial NCT04897841?
This trial is sponsored by University of Wisconsin, Madison, which has 1,039 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.